Cetuximab/Irinotecan Regimen — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	0	0	0	2	0	—	—	2005-08

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 7 hours agoSource updated unknown

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Mutation + MET AmplificationMET KRAS1

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00637091	Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions	completed	Phase 2	40	Asan Medical CenterOTHER	1	Jan 22, 2021	clinicaltrials
NCT00110357	Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors	completed	Phase 1